Alzheimer's & dementia (New York, N. Y.) · 2025
The problem of multiple adjustments in the assessment of minimal clinically important differences.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Oliveira Fabricio Ferreira
Аннотация
INTRODUCTION: Anthropometric, demographic, genetic, and clinical features may affect cognitive, behavioral, and functional decline, while clinical trials seldom consider minimal clinically important differences (MCIDs) in their analyses.
METHODS: MCIDs were reviewed taking into account features that may affect cognitive, behavioral, or functional decline in clinical trials of new disease-modifying therapies.
RESULTS: The higher the number of comparisons of different confounders in statistical analyses, the lower P values will be significant. Proper selection of confounders is crucial to accurately assess MCIDs without compromising statistical significance.
DISCUSSION: Statistical adjustment of the significance of MCIDs according to multiple comparisons is essential for the generalizability of research results. Wider inclusion of confounding variables in the statistics may help bring trial results closer to real-world conditions and improve the prediction of the efficacy of new disease-modifying therapies, though such factors must be carefully selected not to compromise the statistical significance of the analyses.
HIGHLIGHTS: Anthropometric, demographic, and clinical features may affect cognitive, behavioral, and functional decline.Clinical trials seldom take minimal clinically important differences (MCIDs) or their confounders into account.Generalizability of research results requires the assessment of multiple confounding factors.The higher the number of comparisons involved, the lower P values will be considered significant.Use of MCIDs adjusted for confounding factors should be implemented when outcomes are not susceptible to translation into absolute benefits.
METHODS: MCIDs were reviewed taking into account features that may affect cognitive, behavioral, or functional decline in clinical trials of new disease-modifying therapies.
RESULTS: The higher the number of comparisons of different confounders in statistical analyses, the lower P values will be significant. Proper selection of confounders is crucial to accurately assess MCIDs without compromising statistical significance.
DISCUSSION: Statistical adjustment of the significance of MCIDs according to multiple comparisons is essential for the generalizability of research results. Wider inclusion of confounding variables in the statistics may help bring trial results closer to real-world conditions and improve the prediction of the efficacy of new disease-modifying therapies, though such factors must be carefully selected not to compromise the statistical significance of the analyses.
HIGHLIGHTS: Anthropometric, demographic, and clinical features may affect cognitive, behavioral, and functional decline.Clinical trials seldom take minimal clinically important differences (MCIDs) or their confounders into account.Generalizability of research results requires the assessment of multiple confounding factors.The higher the number of comparisons involved, the lower P values will be considered significant.Use of MCIDs adjusted for confounding factors should be implemented when outcomes are not susceptible to translation into absolute benefits.